Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease

Acta Neurochir (Wien). 2006 Jun;148(6):677-9; discussion 679. doi: 10.1007/s00701-006-0772-y. Epub 2006 Apr 7.

Abstract

Pentosan polysulphate, delivered by chronic intraventricular infusion, has been proposed as a potential therapy for human prion disease. The first treated patient is still alive several years after treatment started. Here we describe in detail a case of variant Creutzfeldt-Jakob disease in which this treatment was started at a relatively early stage but had no definite clinical benefit. The patient died from disease progression 16 months after diagnosis and 5 months after pentosan polysulphate treatment was commenced.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Akinetic Mutism / etiology
  • Akinetic Mutism / physiopathology
  • Biopsy
  • Brain / drug effects*
  • Brain / pathology*
  • Brain / physiopathology
  • Cognition Disorders / etiology
  • Cognition Disorders / physiopathology
  • Creutzfeldt-Jakob Syndrome / drug therapy*
  • Creutzfeldt-Jakob Syndrome / physiopathology
  • Creutzfeldt-Jakob Syndrome / psychology
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / administration & dosage
  • Fatal Outcome
  • Female
  • Gait Ataxia / etiology
  • Gait Ataxia / physiopathology
  • Humans
  • Infusion Pumps, Implantable
  • Injections, Intraventricular
  • Magnetic Resonance Imaging
  • Mental Disorders / etiology
  • Mental Disorders / physiopathology
  • Palatine Tonsil / metabolism
  • Palatine Tonsil / physiopathology
  • Pentosan Sulfuric Polyester / administration & dosage*
  • Prions / analysis
  • Prions / metabolism
  • Seizures / etiology
  • Seizures / physiopathology
  • Treatment Failure

Substances

  • Enzyme Inhibitors
  • Prions
  • Pentosan Sulfuric Polyester